MarketIntelligenceCenter.com (Free subscription) | 29/10/2009
Elan Corp (ELN) was downgraded today by analysts at UBS and the stock is now at $5.12, up $0.10 (1.98%) on volume of 10,320,605 shares traded. UBS downgraded the stock today to Neutral, with the stock set a new 52 week low today. Over the last 52 weeks the stock has ranged from a low of $4.61 low today to a high of $9.13 in Janu...
MarketIntelligenceCenter.com (Free subscription) | 21/10/2009
Elan Corp (NYSE: ELN) opened at $6.68. So far today, the stock has hit a low of $6.55 and a high of $6.77. ELN is now trading at $6.65, up $0.19 (2.94%). Over the last 52 weeks the stock has ranged from a low of $4.85 to a high of $10.11. ELN reported earnings this morning, posting a third-quarter profit of $52.3 million or 11 cents per share, on revenue of $287.0 million. Analysts had for...
Reuters UK (Free subscription) | 29/09/2009
NEW YORK (Reuters) - Elan Corp Plc said on Tuesday it received a U.S. Securities and Exchange Commission subpoena over its disclosure of two cases of an often fatal brain disorder tied to use of its Tysabri multiple sclerosis drug.
ireland.com (Free subscription) | 29/09/2009
Elan Corp has today announced a cash tender offer for the existing senior fixed-rate notes of $850 million that is due in 2011.
DealBook (Free subscription) | 15/09/2009
Johnson & Johnson has cut the amount it will pay for its 18.4 percent stake in Irish drugmaker Elan Corp by $115 million to $885 million, Elan confirmed Monday.
Reuters (Free subscription) | 15/09/2009
BOSTON (Reuters) - Johnson & Johnson has cut the amount it will pay for its 18.4 percent stake in Irish drugmaker Elan Corp Plc by $115 million to $885 million, setting Elan up for recriminations from shareholders and possibly even lawsuits.
The Independent (Free subscription) | 15/09/2009
Johnson & Johnson is trying to knock down the price of an 18.4 per cent stake in Irish biotech group Elan Corp after a US judge said the terms of the deal breeched an earlier agreement.
Reuters UK (Free subscription) | 14/09/2009
BOSTON/NEW YORK (Reuters) - U.S. health-care firm Johnson & Johnson is in talks to cut the price of a $1.5 billion deal with Irish drugmaker Elan Corp , a source familiar with the negotiations said on Sunday.
MarketIntelligenceCenter.com (Free subscription) | 04/09/2009
Elan Corp (NYSE: ELN) opened at $6.91. So far today, the stock has hit a low of $6.85 and a high of $7.08. ELN is now trading at $7.07, down $0.28 (-3.81%). Over the last 52 weeks the stock has ranged from a low of $4.85 to a high of $13.10. Shares of ELN are declining this morning after a federal judge ruled last night that the company's recent deal to sell an 18.4% stake to Johnson & Johnson...
Market Watch (Free subscription) | 04/09/2009
LONDON (MarketWatch) -- Irish drugmaker Elan Corp. said Friday that it respects a ruling made by the U.S. court decision that it has breached its collaboration agreement with Biogen Idec for the development and marketing of multiple sclerosis treatment Tysabri. At the end of July Biogen Idec alleged that Elan was in material breach of the deal. Elan said that Biogen Idec's assertion related to its...
Market Wire (Free subscription) | 11/08/2009
NEW DELHI, INDIA (MARKET WIRE) W.S.S. is an online community with a dedicated team of analysts who are providing free in-depth research on North American equities. Our analysts have issued free ratings reports on the following six companies: Briggs & Stratton Corp. (NYSE: BGG), Eaton Vance Corp. (NYSE: EV), Elan Corp. plc (NYSE: ELN), Centex Corporation (NYSE: CTX), First Solar Inc. (NASDAQ: FSLR)...
Business Wire (Free subscription) | 10/08/2009
CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights 3M Company (NYSE: MMM) as the Bull of the Day and Genzyme Corp. (Nasdaq: GENZ) the Bear of the Day. In addition, Zacks Equity Research provides analysis on
The Boston Business Journal (Free subscription) | 06/08/2009
Elan Corp. has filed suit against Biogen Idec, essentially asking a federal court to determine whether Elan has breached a preexisting marketing agreement between the two companies. (ELN) (JNJ)
Jim Cramer's Mad Money (Free subscription) | 05/08/2009
Jim Cramer’s Mad Money Stock Picks for Tuesday August 4 2009. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: Bank of America (BAC) Bristol-Myers Squibb (BMY) ConocoPhillips (COP) Costco (COST) Kimberly-Clark (KMB) Research In Motion (RIMM) SanDisk (SNDK) TransCanada (TRP) US Bancorp (USB) Wells Fargo (WFC) Sell: Elan Corp (ELN) Mylan Laboratories (MYL) NCR...
People Daily (Free subscription) | 22/07/2009
BOSTON: Irish drugmaker Elan Corp Plc gave away more than it told investors in its recent $1.5 billion transaction with healthcare conglomerate Johnson & Johnson. J&J agreed to pay $1 billion for an 18.4 percent stake in Elan, and $500 million for a majority stake in its pipeline of experimental Alzheimer's disease drugs. But Elan gave up more than that to get the deal done. Reuters has learned...
Videos